BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37020070)

  • 1. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
    Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
    Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study.
    Bernardi D; Vatteroni G; Acquaviva A; Valentini M; Sabatino V; Bolengo I; Pellegrini M; Fantò C; Trimboli RM
    AJR Am J Roentgenol; 2022 Dec; 219(6):884-894. PubMed ID: 35731101
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
    Groen EJ; van der Noordaa MEM; Schaapveld M; Sonke GS; Mann RM; van Ramshorst MS; Lips EH; Vrancken Peeters MTFD; van Duijnhoven FH; Wesseling J
    Breast Cancer Res Treat; 2021 Aug; 189(1):213-224. PubMed ID: 33945043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
    Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
    Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of contrast-enhanced mammography in the preoperative detection of ductal carcinoma in situ of the breasts: a comparison with low-energy image and magnetic resonance imaging.
    Wang L; Wang P; Shao H; Li J; Yang Q
    Eur Radiol; 2024 May; 34(5):3342-3351. PubMed ID: 37853174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
    Ploumen RAW; Claassens EL; Kooreman LFS; Keymeulen KBMI; van Kats MACE; Gommers S; Siesling S; van Nijnatten TJA; Smidt ML
    Breast Cancer Res Treat; 2023 Sep; 201(2):227-235. PubMed ID: 37395816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.
    Sun S; van la Parra RFD; Rauch GM; Checka C; Tadros AB; Lucci A; Teshome M; Black D; Hwang RF; Smith BD; Krishnamurthy S; Valero V; Yang WT; Kuerer HM
    Ann Surg Oncol; 2019 Oct; 26(10):3071-3079. PubMed ID: 31342361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer.
    Adrada BE; Huo L; Lane DL; Arribas EM; Resetkova E; Yang W
    Ann Surg Oncol; 2015 Apr; 22(4):1111-7. PubMed ID: 25287438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic sensitivity of dynamic contrast-enhanced magnetic resonance imaging and breast-specific gamma imaging in women with calcified and non-calcified DCIS.
    Kim JS; Lee SM; Cha ES
    Acta Radiol; 2014 Jul; 55(6):668-75. PubMed ID: 24043881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response.
    Santamaría G; Bargalló X; Ganau S; Alonso I; Muñoz M; Mollà M; Fernández PL; Prat A
    Eur J Radiol; 2019 Aug; 117():132-139. PubMed ID: 31307638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
    Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
    PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive values of BI-RADS(®) magnetic resonance imaging (MRI) in the detection of breast ductal carcinoma in situ (DCIS).
    Badan GM; Piato S; Roveda D; de Faria Castro Fleury E
    Eur J Radiol; 2016 Oct; 85(10):1701-1707. PubMed ID: 27666605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Mammographic Microcalcifications with Final Surgical Pathology After Neoadjuvant Chemotherapy for Breast Cancer.
    Azam R; Lim D; Curpen B; Mulligan AM; Hong NL
    Ann Surg Oncol; 2023 Jul; 30(7):4123-4131. PubMed ID: 37029866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy.
    Patel BK; Hilal T; Covington M; Zhang N; Kosiorek HE; Lobbes M; Northfelt DW; Pockaj BA
    Ann Surg Oncol; 2018 May; 25(5):1350-1356. PubMed ID: 29516362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI prediction of neoadjuvant chemotherapy response is equivalent in patients with or without mammographic calcifications: a step towards adapting surgical approach?
    Sella T; Simor B; Adler-Levy Y; Maly B; Kadouri L; Carmon E
    Eur Radiol; 2023 Oct; 33(10):7168-7177. PubMed ID: 37086288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
    Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
    Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
    Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
    Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
    Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
    Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?
    Feliciano Y; Mamtani A; Morrow M; Stempel MM; Patil S; Jochelson MS
    Ann Surg Oncol; 2017 Jun; 24(6):1492-1498. PubMed ID: 28058550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.
    Wazir U; Patani N; Balalaa N; Mokbel K
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.